Kornimate/medical-research-clean huggingface dataset:
role of reverse transcriptase inhibitors in the treatment of psoriasis

Conditions: Psoriasis

Summary: the investigators hypothesize that the inhibition of endogenous reverse transcriptase would: (1) reduce excess cytosolic dna, stress initiating the inflammatory loop at the origin of psoriatic lesions, and (2) interrupt the loop and lighten lesions


Eligibility criteria:
inclusion criteria: * patient suffering from plaque psoriasis for more than a year with at least one active skin lesion\> 4 cm2 in the photo-protected area. * patient using effective contraception (iud, adapted pill, condom, etc.) * the patient must have given their free and informed consent and signed the consent form * the patient must be a member or beneficiary of a health insurance plan exclusion criteria: * patient with another form or stage of psoriasis * patient on anti-cytokine treatment during the 6 months (180 days) before inclusion * patient under systemic treatment based on (1) corticosteroids, (2) antibiotics, (3) methotrexate, ciclosporin, soriatane, hydroxyurea, apremilast or (4) puva, (5) uvb, (6) vitamin d3 during the 4 weeks (28 days) before inclusion * patient on topical corticosteroid or retinoid treatment during the 2 weeks (15 days) before inclusion * patient with renal insufficiency; taking nephrotoxic agents (aminoglycosides, multiple or high doses of nsaids, etc.); creatinine clearance less than 50 ml / min; serum phosphorus below 1.0 mg / dl (0.32 mmol / l). * patient with active viral infection (hbv, hcv and hiv), or uncontrolled acute infection. * patient with hypersensitivity to one of the active substances or to any of the excipients (non-medicinal ingredients). * patient with uncontrolled coagulation disorder, history of keloid scars * patient with an allergy to local anesthetics; any condition likely to interfere at the time of the pre-inclusion visit, with the evaluation of the main objective such as eczema, psychiatric disorders * patient with uncontrolled systemic parameters the subject is participating in an interventional study, or is in a period of exclusion determined by a previous study
miltefosine for brazilian visceral leishmaniasis

Conditions: Kala Azar

Summary: miltefosine will be administered to brazilian patients with kala azar

miltefosine will be administered to brazilian patients with kala azar. both pediatric and adult patients will be studied. patients will be followed for 6 months.

Eligibility criteria:
inclusion criteria: * newly diagnosed (untreated) visceral leishmaniasis with symptomatic disease and visualization of amastigotes in tissue samples or a positive culture. * age: group 1: 2 to 12 years; group 2: 13 to 60 years * sex: male and female patients eligible (no effort to be made to balance the study for gender) exclusion criteria: exclusion criteria safety concerns: * thrombocyte count \<30 x 109/l; * leukocyte count \<1 x 109/l; * hemoglobin \<5 g/100 ml; * asat, alat, ap \>3 times upper limit of normal range; * serum creatinine or bun \>1.5 times upper limit of normal range; * evidence of serious underlying disease (cardiac, renal, hepatic or pulmonary); * immunodeficiency or antibody to hiv; * severe protein and/or caloric malnutrition (kwashiorkor, marasmus); * any non-compensated or uncontrolled condition; * lactation, pregnancy (to be determined by adequate test) or inadequate contraception in females of childbearing potential for treatment period plus 2 months. lack of suitability for the trial: * negative bone marrow aspirate (smear); * any history of prior anti-leishmania therapy; * any condition which compromises ability to comply with the study procedures; * concomitant serious infection other than visceral leishmaniasis (this would include evidence of other conditions associated with splenomegaly such as schistosomiasis or malaria). administrative reasons: * lack of ability or willingness to give informed consent (patient and/or parent / legal representative); * anticipated non-availability for study visits/procedures.

Keywords: miltefosine kala azar brazil
efficacy of combined pharmacotherapy versus solifenacin with vaginal estrogen cream for women with detrusor overactivity

Conditions: Urinary Bladder, Overactive; Effect of Drug

Summary: to investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.

women with detrusor overactivity who were refractory to anti-muscarinics were enrolled for prospective study. patients were divided into two groups: one receive combined pharmacotherapy with solifenacin and mirabegron, and the other received solifenacin and vaginal estrogen cream. incontinence-related symptoms distress and impact on quality of life were evaluated by short form of urinary distress inventory, (udi-6), incontinence impact questionnaire (iiq-7) and overactive bladder symptom score (oabss). objective outcomes include changes from baseline in episodes of daily micturition, urgency, urinary incontinence and nocturia.

Eligibility criteria:
inclusion criteria: * patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study. exclusion criteria: * postvoid urine retention before treatment * women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension * concerns for using estrogen include: women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding. * women who were on hormone replacement therapy within 3 months were also excluded from the study

Keywords: detrusor overactivity combined pharmacotherapy estrogens effectiveness
everolimus in combination with trastuzumab and paclitaxel in the treatment of her2 positive locally advanced or metastatic breast cancer

Conditions: Breast Cancer

Summary: the purpose of this phase iii study was to confirm the value of adding everolimus to weekly paclitaxel and trastuzumab as treatment of her2-overexpressing metastatic breast cancer.


Eligibility criteria:
inclusion criteria: * adult women (≥ 18 years old). * histologically or cytologically confirmed invasive breast carcinoma with local recurrence or radiological evidence of metastatic disease. * must have at least one lesion that can be accurately measured or bone lesions in the absence of measurable disease. * her2+ patients by local laboratory testing (ihc 3+ staining or in situ hybridization positive). * prior trastuzumab and/or chemotherapy (taxanes included) as neo-adjuvant or adjuvant treatment is allowed but should be discontinued \> 12 months prior to randomization. * prior treatment for breast cancer with endocrine therapy (adjuvant or metastatic settings) is allowed but should be discontinued at randomization. patients treated with bisphosphonates at entry or who start bisphosphonates during study may continue this therapy during protocol treatment. * documentation of negative pregnancy test. * organ functions at time of inclusion. exclusion criteria: * prior mtor inhibitors for the treatment of cancer. * other anticancer therapy for locally advanced or metastatic breast cancer except for prior hormonal therapy. * patients with only non-measurable lesions other than bone metastasis (e.g. pleural effusion, ascites, etc). * radiotherapy to ≥ 25% of the bone marrow within 4 weeks prior to randomization * history of central nervous system metastasis. * impairment of gastrointestinal (gi) function or gi disease or active ulceration of the upper gastrointestinal tract. * serious peripheral neuropathy. * cardiac disease or dysfunction. * uncontrolled hypertension. * hiv. * pregnant,

Keywords: breast cancer her2+ mtor everolimus rad001 first line metastatic locally advanced trastuzumab paclitaxel first line therapy her2 positive metastatic breast cancer
effect of the plasma ebv dna change during chemoradiotherapy in nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma

Summary: epstein-barr virus (ebv) has been proven to process a strong association in patient of nasopharyngeal carcinoma (npc). monitoring plasma ebv dna in npc patients can provide reliable informations in early detecting tumor recurrence or risk grouping.

ebv dna has strongly association in npc patient' disease status. it can provide informations of disease relapse or risks classification. in this study, we will investigate the impact of plasma ebv dna concentration change during chemoradiotherapy on initial tumor response and long-term survival in patients with advanced nasopharyngeal carcinoma

Eligibility criteria:
inclusion criteria: 1. histological proven npc. 2. 2010 american joint committee on cancer (ajcc) stage ii-ivb. 3. age ≧ 20 years old. 4. performance status of eastern cooperative oncology group (ecog) ≦ 2. 5. adequate liver, renal, and bone marrow functions 5.1 serum total bilirubin level ≦ 2.5 mg/dl. 5.2 serum creatinine ≦ 1.6 mg/dl or calculated creatinine clearance rate (ccr) ≧ 60 cc/min. 5.3 white blood cell count (wbc) ≧ 3,000/micro-ml. 5.4 platelet count ≧ 100,000/micro-ml. 6. pre-treatment plasma ebv dna \> 0 copies/ml 7. signed informed consent. exclusion criteria: 1. presence of distant metastasis. 2. previous radiotherapy or chemotherapy. 3. history of a malignancy except those treated with curative intent for skin cancer (other than melanoma), in situ cervical cancer, ductal carcinoma in situ (dcis) of the breast. 4. severe cardiopulmonary diseases (unstable angina and/or congestive heart failure or peripheral vascular disease requiring hospitalization within the last 12 months; chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization) or clinically significant psychiatric disorders. 5. female patients who are pregnant or lactating.

Keywords: nasopharyngeal carcinoma ebv dna chemoradiotherapy
prevalence of anticipatory nausea and vomiting in cancer patients exposed to highly emetogenic chemotherapy

Conditions: Chemotherapy-induced Nausea and Vomiting

Summary: chemotherapy induced nausea and vomiting are common adverse events related to oncologic treatments. it can have deleterious effect on patients' quality of life and could lead to dose reductions and/or discontinuation of treatment. this study aims to quantify the prevalence of nausea and vomiting induced by highly emetogenic chemotherapy in patients who had adequate antiemetic prophylaxis, also to describe the epidemiologic profile and identify predisposing factors.

the investigators will track patients in the first and second cycles of chemotherapy. information regarding comorbidities, medical history and sociodemographic characteristics will be collected. the impact of nausea and vomiting induced by the treatment on patient's quality of life will be evaluated using the questionnaire functional living index-emesis - flie.

Eligibility criteria:
inclusion criteria: * patients with histological confirmation of cancer; * patients who will start chemotherapy with a high-grade emetogenic scheme and who have received adequate antiemetic prophylaxis; * no previous cancer treatment for the current diagnosis (excluding surgery); exclusion criteria: * patients who have an inability to answer the questionnaire, due to lack of discernment to answer the questions reliably; * patients who report vomiting during the 24 hours prior to the first cycle of chemotherapy treatment; * patients who have a disease or condition that could cause emesis (ie, metastasis in the central nervous system, gastrointestinal obstruction or metabolic and electrolyte imbalances); * patients using opioids or illicit drugs; * alcoholism;

Keywords: nausea antiemetics antineoplastic quality of life
pain response to cannabidiol in induced acute nociceptive pain, allodynia and hyperalgesia by using a model mimicking acute pain in healthy adults

Conditions: Pain Sensation; Hyperalgesia; Allodynia

Summary: this study is to investigate the effect of cbd on acute pain in healthy volunteers in a well-established acute pain model.

there are no studies investigating cannabidiol (cbd) in an acute pain model in human beings. this is however of great clinical value because: 1. patients are often treated insufficiently with the commonly used analgesics in acute pain therapy or the available selection of analgesics is limited by their contraindications and side-effects. 2. cbd could be an option to optimize pain therapy if the pain relief is not satisfactory. 3. cbd in contrast to ∆9-tetrahydrocannabinol (thc) has only few side effects and due to a possible dose reduction of other analgesics patients might benefit from a better side-effect profile. this study is to investigate the effect of cbd on acute pain in healthy volunteers in a well-established acute pain model.

Eligibility criteria:
inclusion criteria: * healthy adults * bmi between 18.5 until 25 kg/m2 * able to understand the study and the nrs scale * able to give informed consent exclusion criteria: * regular consumption of cannabinoids or other drugs / substances * regular intake of medications potentially interfering with pain sensation (analgesics, antihistamines, calcium and potassium channel blockers, serotonin / noradrenaline reuptake inhibitors, corticosteroids) * neuropathy * chronic pain * neuromuscular disease * psychiatric disease * known or suspected kidney or liver disease * pregnancy/ lactation * allergy / hypersensitivity to cannabidiol

Keywords: cannabidiol (cbd)
determination of dispersion in ultrasound guided quadratus lumborum block in cadavers

Conditions: Nerve Block

Summary: lumbar quadrant blockade is a recent analgesic technique consisting of the injection of local anesthetic around the lumbar square muscle. it was initially described as a technique for abdominal wall analgesia, but later studies have increased the range of indications for laparoscopic and lower limb surgeries. there are several techniques described but with differences in the literature at the point of injection and volume of anesthetic. the exact mechanism of visceral analgesia has not yet been determined. the objective of this study is to determine the dispersion of local anesthetic as a variable dependent on the volume of local anesthetic and injection site and elucidate the mechanisms of analgesia.

after the free and informed consent signed by the family authorizing the procedure, demographic and clinical data will be collected from the medical records of the deceased. the corpse will be weighed, measured and placed on the autopsy table. blockade randomization (qlb 2 or qlb 3) and volume of local anesthetic (10ml, 20ml, 30ml) will be performed for each side. injection in the anterior or posterior plane to the lumbar quadrant muscle will be performed by anesthesiologists experienced in the technique with ultrasound aid. a colouring solution will be used. after confirming the correct needle position, the previously randomized volumes will be injected. after the blockage, the corpse will be placed in the supine position and will be submitted to autopsy by standard procedure. after removal of the thoracic and abdominal viscera, the investigators will verify the dispersion of the local anesthetic. photographic records will be made and the number of levels by which the solution dispersed will be annotated, calculating the number of cranial and caudal levels. the corpse will then have its autopsy procedure completed, with the placement of the viscera and incision closure according to the service standard.

Eligibility criteria:
inclusion criteria: * fresh corpses - not subjected to a formaldehyde process or frozen for more than 24 hours * age ≥ 18 years. * free, informed and informed consent signed by relatives or guardians of the body. * height\> 150 cm and \<190 cm exclusion criteria: * previous spinal surgery. * significant spinal deformity * body mass index (bmi) ≥ 35 kg / m2 * absence of relatives or guardians who can sign the written consent
tcm daoyin in the treatment of patients with anxiety state

Conditions: Anxiety State

Summary: in recent years, the number of people with symptoms of anxiety are on the rise. tcm daoyin is a promising intervention for anxiety. this study is designed to allow researchers to better understand the changes in anxiety symptom, brain activity, and immune function during patients with anxiety states receiving tcm daoyin intervention. thus, the aims of the prospective randomized study are: (1) to examine the effects of tcm daoyin training on reducing symptoms of anxiety, (2) to measure brain activity by using functional magnetic resonance imaging (fmri), and (3) to assess immune function.

anxiety is one of the most common mental health problems in the world. but there is a lack of sufficient no-drug intervention for relieving the anxious symptoms. the study focuses on mild and early anxiety disorder, which symptoms are not sufficiently severe, numerous, or persistent to justify a diagnosis of an anxiety disorder. tcm daoyin is a form of mind-body exercise with a profound philosophical foundation rooted in chinese culture. previous studies have provided some evidence of beneficial effects on tcm daoyin for anxiety, such as baduanjin and liuzijue. however, the effects and neurophysiology mechanisms of tcm daoyin on patients with anxiety state are yet to be further investigated. this is a two-group prospective, randomized, assessor-blinded trial, planning to enroll 20 participants (10 for tcm daoyin intervention group receiving health education plus a tcm daoyin training program, and 10 for health education control group only receiving health education). the aims of the prospective randomized study are: (1) to examine the effects of tcm daoyin training on reducing symptoms of anxiety, (2) to measure brain activity by using functional magnetic resonance imaging (fmri), and (3) to assess immune function.

Eligibility criteria:
inclusion criteria: * subject with a primary mental health complaint of anxiety. * anxiety 14≤hama-14≤29, depression 7≤hamd-17\<14. * subject has no history of psychotropic medication or has been off medication for more than 6 months. * right-handed, aged 18 to 65, male or female. * subject has a clear mind and the ability to lead an independent life. * subject agrees to participate in fmri scan and provide signed informed consent. exclusion criteria: * subject with definite clinical diagnosis of anxiety disorder and depression disorder by icd-10. * subject with bipolar disorder, psychotic disorder (e.g., schizophrenia), organic mental disorder (e.g., alzheimer's disease). * subject with alcohol abuse, substance dependence and suicidal ideation in past-year, or currently taking psychiatric medication, or current serious suicidal attempt. * subject with serious current unstable medical illness. * subject has claustrophobia, or any contraindication unable or unwilling to participate in fmri scan. * subject is clinically unable to participate in tcm daoyin training program. * subject is pregnant or lactating women.

Keywords: tcm daoyin anxiety randomized controlled trial
a study to compare effects and safety of ct-p51 and keytruda in patients with previously untreated metastatic lung cancer

Conditions: Non Squamous Non Small Cell Lung Cancer

Summary: the goal of this phase 3 clinical trial is to compare efficacy and safety of ct-p51 and european union (eu) approved keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsnsclc.


Eligibility criteria:
inclusion criteria: * stage iv, non squamous nsclc * have not received any prior systemic anti-cancer therapy for metastatic nsclc * have at least 1 measurable lesion per recist version 1.1 exclusion criteria: * have predominantly squamous cell histology nsclc. * hypersensitivity or contraindication to any component of the study drug, pemetrexed and cisplatin or carboplatin
cognitive-existential group therapy to reduce fear of cancer recurrence: a rct study

Conditions: Breast Neoplasms; Ovarian Neoplasms; Endometrial Neoplasms; Uterine Cervical Neoplasms

Summary: studies show that cancer survivors have unmet needs, the most frequently cited being fear of recurrence (fcr). moderate to high levels of fcr have been reported by as much as 49% of cancer patients and are more prevalent among women. fcr is associated with psychological distress, lower quality of life, and increased health care utilization. little evidence exists that these problems are being addressed by current medical management.

the present study aims to further test this cognitive-existential group intervention for fcr in a randomized control clinical trial with women with breast or gynecological cancer. participants will be recruited from princess margaret hospital, mount sinai hospital, the jewish general hospital, and the ottawa hospital. 144 cancer patients will be randomized to either receive the 6 week cognitive-existential group intervention or to a control group. the control group will also consist of six weekly sessions during which participants will discuss the challenges of living with a cancer diagnosis, but without a clear focus on fcr. women randomized to participate in the study will a) be 18 years or older; b) have a first diagnosis of breast or gynecological cancer with stages between iiii; c) be disease free at the start of the group; d) gave clinical levels of fear of cancer recurrence; e) have clinical levels of distress; and f) have completed their cancer treatment.

Eligibility criteria:
inclusion criteria: 1. first diagnosis of bc or gc with stages between i-iii; 2. disease-free at the start of the group; 3. women aged 18 years or older; 4. completion of treatment, with the exception of adjuvant chemotherapy or hormonal replacement therapy exclusion criteria: 1. non-english speakers 2. previous cancer recurrence 3. enrolled in another group psychotherapy at the time of the start of the study or during the course of the 6 sessions 4. unresolved mental health disorder judged to be clinically contra-indicated and/or likely to affect the group work, based on disclosure by the potential participant or clinically identified by the group leader.

Keywords: breast cancer gynecological cancer fear of cancer recurrence clinical trial randomized controlled trial group therapy intervention cognitive-existential